Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9237118 | 1.00 | PSMB5 (0.60) | PSMB5L3MBTL1ATMLMNATDP1 | |
| SCHEMBL23221689 | 1.00 | PSMB5 (0.60) | PSMB5L3MBTL1ATMLMNATDP1 | |
| SCHEMBL5487377 | 0.99 | L3MBTL1 (0.61) | PSMB5L3MBTL1ATMLMNATDP1 | |
| SCHEMBL23221679 | 0.94 | LMNA (0.66) | PSMB5L3MBTL1ATMLMNATDP1 | |
| SCHEMBL23221677 | 0.94 | LMNA (0.66) | PSMB5L3MBTL1ATMLMNATDP1 | |
| SCHEMBL13525012 | 0.89 | ATM (0.60) | L3MBTL1ATMLMNATDP1GAA | |
| SCHEMBL13033926 | 0.88 | LMNA (0.56) | L3MBTL1ATMLMNATDP1GAA | |
| SCHEMBL8682005 | 0.88 | L3MBTL1 (0.58) | PSMB5L3MBTL1LMNATDP1ALDH1A1 | |
| SCHEMBL12578884 | 0.87 | LMNA (0.80) | PSMB5L3MBTL1ATMLMNATDP1 | |
| SCHEMBL3712356 | 0.87 | LMNA (0.80) | PSMB5L3MBTL1ATMLMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| EP-3805237-A1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019228299-A1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | 江苏正大丰海制药有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | SEM1, VIP, PSMB11 | PSMB5 38/4885L3MBTL1 2190/4885ATM 4037/4885 |
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | SEM1, VIP, PSMB11 | PSMB5 38/4885L3MBTL1 2190/4885ATM 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.